Digirad is a San Diego-based company that is developing a mobilegamma camera that uses solid-state digital detectors rather thanscintillation crystals and photomultiplier tubes to detect scintillationevents. The technology could represent the next step
Digirad is a San Diego-based company that is developing a mobilegamma camera that uses solid-state digital detectors rather thanscintillation crystals and photomultiplier tubes to detect scintillationevents. The technology could represent the next step in nuclearmedicine detector technology by offering improved image resolution(SCAN 7/6/95).
Digirad will display a detector head from its DigiCam NotebookImager, a gamma camera under development. When completed, thecamera will be mounted on a wheeled cart about the size of anultrasound scanner and will employ a small cadmium zinc telluridedetector for organ-specific imaging. The detector head measuresabout 8 x 8 inches and weighs 25 pounds with collimator. Digiradhopes to file a 510(k) application for DigiCam Notebook Imagerin 1996.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.